Human Vaccines & Immunotherapeutics

Human Vaccines & Immunotherapeutics is published by Landes Bioscience and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Vaccine Coverage and Hesitancy, Influenza Virus Research Studies and SARS-CoV-2 and COVID-19 Research, together about 34.8% of its articles. Its main subfields are Epidemiology. (generated from OpenAlex topic counts and CAS ranking data)

Human Vaccines & Immunotherapeutics is an open access peer-reviewed journal publishing international research into human vaccinology and immunotherapy, including novel and experimental vaccine and immunotherapeutics exploration. The journal's audience includes clinicians, researchers, medical professionals, epidemiologists, public health workers, biotech and pharmaceutical companies, and drug regulators interested in vaccinology and immunotherapy. Human Vaccines & Immunotherapeutics is affiliated with the International Society for Vaccines (ISV) and the Association for Cancer Immunotherapy (CIMT). The aim of Human Vaccines & Immunotherapeutics is to provide a platform to present and discuss developments in human vaccinology and immunotherapy. The journal covers the following topics: Research and development and new technologies for novel vaccines and immunotherapeutics Vaccines and immunotherapeutics for treating both infectious and non-infectious diseases, e.g. cancer Preclinical studies and assays Clinical trials for vaccines and immunotherapeutics Disease processes and mechanisms, including biomarkers Licensed products and their use in the field Knowledge, attitude, practices, acceptance and hesitation for vaccination and immunotherapy Interventions and policy Impact of licensed vaccines and immunotherapeutics on disease and health economics Safety and surveillance of licensed vaccines and immunotherapeutics Prevention and treatment in the developing world Epidemiology and pharmaco-economics Human Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rapid Communications, Data Notes, Article Commentaries, Meeting Reports, Plain Language Summaries of Publication and Editorials (Editors and Guest Advisors only) for publication. The journal operates a single-anonymized peer review policy. Note that bibliometric studies will only occasionally be considered and must provide a deep, rigorous analysis of current and future topics in order to bring value to the field. Bibliometric studies must be validated using the authors' own data through replication in an original sample. Pharmacological and bioinformatics studies based solely on in silico analyses without experimental validation are not considered. The Journal does not accept Traditional Chinese Medicine studies. The journal accepts replication studies, provided that the study adds significantly to the body of

From the journal's Aims & Scope

Research area (LetPub): BIOTECHNOLOGY & APPLIED MICROBIOLOGY-IMMUNOLOGY

Editor-in-chief Ronald EllisPublisher website

Editorial board by country: 22 in mainland China (about 20%); most named United States 35, Mainland China 22, Italy 8, Australia 6, United Kingdom 5 (111 members with a country) Editorial board ↗Publisher website · 2026-10-03

CAS Journal Ranking

JCR / CiteScore quartiles on the journal's website

• JCR Q2 · best quartile · 2025
• CiteScore Q1 · 2025

Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website

Database indexing

SCIEScopusDOAJLetPub

International journal early-warning lists: not listed in any editionLetPub

Indexing the journal's website claims

Web of ScienceMEDLINEPubMedEmbasePublisher website

Other: Adis International Ltd. - Reactions Weekly (Online), EBSCOhost - Biological Abstracts (Online)

As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Impact

Impact factor

4.13LetPub · 2026-09-13

Impact factor (publisher) 2025

4.2Publisher website · 2026-10-03

5-year impact factor (publisher) 2025

3.7Publisher website · 2026-10-03

CiteScore 2026-06

7.4LetPub · 2026-09-13

CiteScore (publisher) 2025

7.4Publisher website · 2026-10-03

SJR 2026-06

1.09LetPub · 2026-09-13

SJR (publisher) 2025

1.09Publisher website · 2026-10-03

SNIP 2026-06

1.08LetPub · 2026-09-13

SNIP (publisher) 2025

1.08Publisher website · 2026-10-03

h-index

43LetPub · 2026-09-13

h-index

132OpenAlex · 2026-10-01

i10-index

3,763OpenAlex · 2026-10-01

2-year mean citedness

4.38OpenAlex · 2026-10-01

Self-citation rate

9.5%LetPub · 2026-09-13

Share of gold OA articles

100%LetPub · 2026-09-13

Volume

Articles per year

514LetPub · 2026-09-13

Articles per year (publisher)

1Publisher website · 2026-10-03

Downloads per year (publisher)

3,600,000Publisher website · 2026-10-03

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Other sources

Average review time (community reports)

3–6 weeksLetPub · 2026-09-13

Average acceptance (community reports)

EasyLetPub · 2026-09-13

Acceptance rate (publisher)

50%Publisher website · 2026-10-03

Submission to first decision

27 daysPublisher website · 2026-10-03

First decision after review

49 daysPublisher website · 2026-10-03

Acceptance to publication

16 daysPublisher website · 2026-10-03

Submission to publication (journal-reported)

about 11 weeksDOAJ · 2026-10-25

Peer review

Single anonymous peer reviewDOAJ

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

• APC information ↗DOAJ
• Fee waivers ↗DOAJ
• Open access statement ↗DOAJ
• License & copyright ↗DOAJ

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.

Publisher

Landes Bioscience

Country or region

UNITED STATES

Language

English

ISSN

2164-5515

Electronic ISSN

2164-554X

Latest issue on the website

Volume 22, Issue 1 (2026)

Official links

• Journal homepage ↗DOAJ
• Submission system ↗Publisher website
• Author guidelines ↗DOAJ
• Aims & Scope ↗DOAJ
• Special issues ↗Publisher website
• APC information ↗DOAJ
• Fee waivers ↗DOAJ
• Open access statement ↗DOAJ
• License & copyright ↗DOAJ
• Peer review process ↗DOAJ
• Editorial board ↗DOAJ
• Plagiarism policy ↗DOAJ